GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.

Tim Higgins is a business columnist for The Wall Street Journal, frequent contributor to CNBC, and author of books about Apple (“iWar”) and Tesla (“Power Play”). He also co-hosts “Bold ...

Tim David's scintillating, unbeaten century helped Australia make a total mockery of West Indies' lofty 214/4 as they chased it down with 23 balls to spare.